DTT : 19 Years and Counting …

As Editor-in-Chief of Diabetes Technology & Therapeutics (DTT), I am pleased that our journal continues to grow rapidly, bringing you the most important and relevant original articles, reviews, and expert commentaries in our field. Several new pharmacotherapies and devices (continuous glucose monitors and insulin pumps) have been added to the armamentarium for treatment of diabetes in the past two decades. Many of us never imagined that we will see an artificial pancreas system available in the near future. However, the Federal Drug Administration approved the first Artificial Pancreas System (Hybrid Closed-Loop-670G) in September 2016 in an unprecedented 3-month review which normally takes 1+ year.

The data published in DTT articles are cited frequently in key meetings around the globe by the leading experts in diabetes and new technology. Our journal has grown very rapidly at a stunning pace, and transparent peer-review process is our highest priority and greatest challenge. I am proud to say that our peer-review turnaround is a remarkably short 16-day from submission to first decision. We are fortunate to have very fine support from Ananda Basu (Andy) and Rita Basu, who perform the invaluable roles of Associate Editor with tremendous energy and rigor, enabling us to move articles through peer review even more quickly.

DTT has high visibility throughout the world, with readers in over 170 countries. Papers from the journal have been downloaded 160,000+ times thus far this year, a tremendous 35% increase over last year. If you publish in DTT you can be assured that your article will have tremendous visibility and impact around the globe.

This special supplement includes the prestigious Advanced Technologies & Treatments for Diabetes (ATTD) 2016 Yearbook, an invaluable resource spotlighting and interpreting the most exciting and impactful literature published in the field. Each chapter is authored by a leading international opinion leader and presents a concise summary of the most important articles published from July 2015 to June 2016, with invaluable expert commentary. Publishing the Yearbook in DTT is vital because it means the articles are searchable on PubMed, Google, and other search engines.

I am grateful for the hard work by all authors, and especially Moshe Phillip's and Tadej Battelino's ongoing leadership in organizing this critical resource for our field on an annual basis in conjunction with their outstanding meeting, the 10^th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2017) will take place in Paris, February 15–18, 2017.

The abstracts from the meeting are also included in this online supplement, giving readers and attendees a rich view into new and exciting work in technology and therapeutics.

DTT continues to be the official journal of the ATTD. Our partnership is very productive and effective in aligning the leading conference and the leading journal in the field of new technologies and treatments for diabetes.

I look forward to your ongoing active participation, including your manuscript submissions and commentaries, in the journal.